Kedudukan dalam Saham
#35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Harga Saham
$0.108
Disegerakkan terakhir: 2023-01-23
Perubahan (1 hari)
-10.00%
Perubahan (1 tahun)
0.00%
Perdagangan Tricida, Inc. (TCDA)
Harga TCDA dengan permodalan pasaran b
Modal pasaran bagi Tricida, Inc.(TCDA)
Modal Pasaran: $4.56M
Sehingga August 2026, Tricida, Inc. mempunyai modal pasaran sebanyak $4.56M. Ini menjadikan Tricida, Inc. syarikat ke-35026th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Tricida, Inc. dari 2018 hingga 2026
TCDA berbanding dengan 5 teratas yang paling popular stocks
| Harga TCDA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+119,424,252.46%
|
|
|
|
|
$4.490T
|
+98,354,771.67%
|
|
|
|
|
$4.162T
|
+91,178,334.11%
|
|
|
|
|
$3.676T
|
+80,530,983.42%
|
|
|
|
|
$2.833T
|
+62,058,316.97%
|
